Matrix One, a prominent digital solutions provider serving the medical devices and life sciences sector and supported by Lauxera Capital Partners, has completed the acquisition of dokspot GmbH, a leading developer of electronic Instructions for Use (eIFU). This acquisition will see dokspot’s technology fully integrated into Matrix One’s product suite and rebranded as Matrix eIFU, strengthening the company’s mission to provide life sciences organizations with advanced digital tools that meet evolving global regulatory standards.
Health Technology Insights: Orsini and Dos Rx Partner to Support International Medical Travel Facilitation
Louis Albert, CEO of Matrix One, stated that the acquisition represents a significant step in the company’s vision to build a leading digital platform for life sciences companies. He explained that Matrix One aims to assist organizations in transitioning from traditional paper-based IFUs to electronic formats, offering substantial cost reductions, streamlined processes, and a measurable reduction in paper consumption and associated CO2 emissions. Albert emphasized that this integration aligns with both operational efficiency and environmental responsibility.
Health Technology Insights: WindRose Health Investors Makes Strategic Investment in Stellus Rx
Hans Strobel, CEO of dokspot, commented that joining Matrix One represents an exciting opportunity to expand the global reach of their technology. He highlighted that the shared goal of simplifying workflows through digital innovation will accelerate the adoption of electronic IFUs worldwide, allowing manufacturers to operate more efficiently, reduce environmental impact, and maintain confidence in regulatory compliance.
Matrix eIFU is positioned to help life sciences companies meet regulatory expectations while improving operational resilience and sustainability. By moving from paper-based to electronic IFUs, manufacturers can reduce administrative and logistics burdens, ensure healthcare professionals have access to the latest updates in real time, strengthen post-market surveillance documentation, minimize environmental impact, and provide secure, traceable access to IFUs and regulatory records. This solution aims to deliver both practical benefits for compliance and measurable contributions to sustainability efforts in the life sciences industry.
Health Technology Insights: GC Biopharma Ships First Doses of ‘BARYTHRAX inj.’ Anthrax Vaccine
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
